Waterloo Capital’s AbbVie ABBV Stock Holding History

Waterloo Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.58M	Sell	21,054 -1,374	-6%	-$305K	0.32%	75
2025 Q4	$5.12M	Buy	22,428 +437	+2%	+$99.5K	0.37%	61
2025 Q3	$5.09M	Buy	21,991 +1,372	+7%	+$279K	0.38%	61
2025 Q2	$3.83M	Buy	20,619 +2,119	+11%	+$394K	0.31%	76
2025 Q1	$3.88M	Buy	18,500 +3,125	+20%	+$608K	0.36%	71
2024 Q4	$2.73M	Buy	15,375 +307	+2%	+$56.4K	0.29%	88
2024 Q3	$2.98M	Buy	15,068 +4,197	+39%	+$783K	0.32%	78
2024 Q2	$1.86M	Sell	10,871 -1,366	-11%	-$226K	0.22%	102
2024 Q1	$2.23M	Buy	12,237 +95	+0.8%	+$16.4K	0.28%	87
2023 Q4	$1.88M	Buy	12,142 +10,333	+571%	+$1.51M	0.3%	82
2023 Q3	$270K	Buy	+1,809	New	+$266K	0.08%	155
2023 Q2	–	Sell	-2,529	Closed	-$403K	–	207
2023 Q1	$403K	Buy	+2,529	New	+$387K	0.12%	102

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Waterloo Capital's ABBV Position: Q1 2026 in Review

Waterloo Capital reduced its AbbVie (ABBV) stake by 6.1% in Q1 2026, selling an estimated $305K and leaving 21,054 shares worth $4.58M. The position accounts for 0.32% of the portfolio, ranked #75.

Waterloo Capital first reported a position in ABBV in Q1 2023 and has held it in 12 quarters since. The position peaked at $5.12M in Q4 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Waterloo Capital held 21,054 shares of AbbVie worth $4.58M as of Q1 2026.
Waterloo Capital sold 1,374 AbbVie shares in Q1 2026, an estimated $305K.
AbbVie made up 0.32% of Waterloo Capital's portfolio in Q1 2026, its #75 holding.
Waterloo Capital first reported a position in AbbVie in Q1 2023 and has held it in 12 quarters since.
Waterloo Capital's AbbVie position peaked at $5.12M in Q4 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Waterloo Capital's 13F filing for Q1 2026, filed 12 May 2026.